2007
DOI: 10.1007/s10517-007-0172-1
|View full text |Cite
|
Sign up to set email alerts
|

Use of interferon-α-induced dendritic cells in the therapy of patients with malignant brain gliomas

Abstract: Clinical and immunological analysis of the efficiency of combined immunotherapy with the use dendritic cells for the treatment of malignant glioma of the brain was carried out. Dendritic cells generated in the presence of granulocyte-macrophage CSF and IFN-alpha retain their functional characteristics in patients with gliomas, which suggests the possibility of their use for the treatment of malignant tumors (glioma) of the brain. Combined therapy using interferon-induced dendritic cells was associated with gen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 18 publications
0
13
0
Order By: Relevance
“…Recent studies have shown that dendritic cells (DCs) as innate immunity cells have cytotoxic functions and can suppress tumor cell growth [13]. This activity of DCs is mediated through expression of TNF family pro-apoptogenic molecules [13] and is enhanced in response to interferons [4, 5].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Recent studies have shown that dendritic cells (DCs) as innate immunity cells have cytotoxic functions and can suppress tumor cell growth [13]. This activity of DCs is mediated through expression of TNF family pro-apoptogenic molecules [13] and is enhanced in response to interferons [4, 5].…”
Section: Introductionmentioning
confidence: 99%
“…This activity of DCs is mediated through expression of TNF family pro-apoptogenic molecules [13] and is enhanced in response to interferons [4, 5]. It was also shown that DCs are capable of expressing coinhibitory molecule B7-H1, which is a ligand for receptor-programmed cell death 1 (PD-1) [6, 7].…”
Section: Introductionmentioning
confidence: 99%
“…To date, there are a number of approaches for generating DCs in vitro, including preparation of DCs from peripheral blood monocytes and bone marrow progenitors (CD34 + cells) (18). Furthermore, a wide range of factors may be used for differentiation and maturation of DCs (GM-CSF, IL-4, interferon-α, IL-2, IL-6, IL-15, TGF-α, stem cell factor, FLT-3 ligand and prostaglandin E2) that may facilitate, in a combination or individually, the generation of DCs from monocytes or CD34 + cells (19)(20)(21)(22)(23). The present study suggested that there is some danger in using numerous factors for differentiation and maturation of DCs that can lead to the production of DC subsets with a variety of phenotypes and functions.…”
Section: Discussionmentioning
confidence: 99%
“…Actually, IFN-DCs, as compared with the IL-4-induced DCs, are known for their high migration activity, stability in the absence of growth factors and low expression of DC-SIGN molecules, capable of binding M. tuberculosis [7,32]. The major promise of DC vaccines for induction of antigen-specific immune response is actively discussed not only in cancer, but also in chronic infections [33][34][35]. However, the clinical development of therapeutic vaccines for TB patients requires the preliminary testing and in vitro correction of impaired DC functions.…”
Section: Citationmentioning
confidence: 99%